Date Title Description PDF
24 Oct 2024 On corporate transactions ROVI completes the strategic review of its CDMO business Download
31 Jul 2024 On P&L The Company releases the press release related to the first half 2024 financial results Download
31 Jul 2024 On P&L The Company releases the first half 2024 financial results presentation Download
26 Jun 2024 On corporate transactions ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives Download
24 Jun 2024 On business and financial situation ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth Download

Pages

Date Title Description PDF
11 Aug 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 3 August and 10 August 2023 Download
03 Aug 2023 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 26 July 2023 and 2 August 2023 Download
28 Jul 2023 On business and financial situation ROVI informs on the evaluation process to obtain marketing authorisation for Risvan® Download
05 Jul 2023 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2023 Download
26 Jun 2023 Other relevant information The Company informs about the dividends payment Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages